Combination of Human Monoclonal Antibodies Against SARS Coronavirus
Author Information
Author(s): Jan ter Meulen, Edward N van den Brink, Leo L. M Poon, Willem E Marissen, Cynthia S. W Leung, Freek Cox, Chung Y Cheung, Arjen Q Bakker, Johannes A Bogaards, Els van Deventer, Wolfgang Preiser, Hans Wilhelm Doerr, Vincent T Chow, John de Kruif, Joseph S. M Peiris, Jaap Goudsmit
Primary Institution: Crucell Holland B.V.
Hypothesis
Can a combination of human monoclonal antibodies provide effective neutralization against SARS-CoV and its escape variants?
Conclusion
The combination of two noncompeting human monoclonal antibodies CR3014 and CR3022 potentially controls immune escape and extends the breadth of protection.
Supporting Evidence
- CR3014 completely prevented lung pathology in ferrets infected with SARS-CoV.
- CR3022 neutralized CR3014 escape variants and did not compete for binding.
- The combination of CR3014 and CR3022 showed synergistic effects in neutralizing SARS-CoV.
- CR3022 extended the breadth of protection against different SARS-CoV strains.
Takeaway
Researchers found that using two different antibodies together can help fight the SARS virus better than using just one, making it harder for the virus to escape treatment.
Methodology
The study involved generating and testing human monoclonal antibodies against SARS-CoV in vitro, assessing their neutralization potency and synergy.
Potential Biases
Potential bias due to funding from Crucell Holland BV, which was involved in the study design and data analysis.
Limitations
The study's findings need to be validated in animal models before human application.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website